Livmarli was Mirum Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $360.01M of $521.31M (69%).
| Product and Service | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Livmarli | $75.06M | $141.80M | $213.30M | $360.01M | |
| Bile Acid Medicines | — | $37.08M | $123.11M | $161.31M | |
| License Revenue | — | — | — | — | |
| License & Other Revenue | $2.00M | $7.50M | $479.00K | — | |
| Total | $77.06M | $186.37M | $336.89M | $521.31M |
Mirum Pharmaceuticals brought in $521.31M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Mirum Pharmaceuticals regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $336.89M. Livmarli was the largest at $360.01M (69.1%), ahead of Bile Acid Medicines at $161.31M (30.9%).
Compared with fiscal 2024, Livmarli grew 68.8% to $360.01M and Bile Acid Medicines grew 31.0% to $161.31M.
Mirum Pharmaceuticals began breaking out Bile Acid Medicines in fiscal 2023, when it brought in $37.08M. Mirum Pharmaceuticals stopped reporting License & Other Revenue as a separate line after fiscal 2024, when it brought in $479.00K.
United States was Mirum Pharmaceuticals’s largest region in fiscal 2025, bringing in $401.55M of $521.31M (77%).
| Geography | FY 2024 | FY 2025 |
|---|---|---|
| United States | $274.17M | $401.55M |
| Rest Of The World | $62.24M | $119.77M |
| Total | $336.41M | $521.31M |
Mirum Pharmaceuticals brought in $521.31M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 55.0% from $336.41M in fiscal 2024. United States was the largest at $401.55M (77.0%), ahead of Rest Of The World at $119.77M (23.0%).
Compared with fiscal 2024, Rest Of The World grew 92.4% to $119.77M and United States grew 46.5% to $401.55M.
Mirum Pharmaceuticals (MIRM) reports its revenue by product and service and by geography. In fiscal 2025, Livmarli was its largest product and service line, bringing in $360.01M (69.1% of the total), followed by Bile Acid Medicines at $161.31M (30.9%).
Livmarli was Mirum Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $360.01M, or 69.1% of the $521.31M total across its two product and service lines.
United States was Mirum Pharmaceuticals' largest region in fiscal 2025, bringing in $401.55M, or 77.0% of the $521.31M total across its two regions.
Rest Of The World grew faster than United States in fiscal 2025, up 92.4% from $62.24M to $119.77M. United States grew 46.5% to $401.55M.
Every figure comes from Mirum Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Mirum Pharmaceuticals gives it, and years follow its fiscal calendar.
Mirum Pharmaceuticals' revenue by product and service goes back to fiscal 2021, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.